Tom Blydt-Hansen

Associate Professor

Relevant Degree Programs



Dr. Tom Blydt-Hansen is a Clinical Pediatric Nephrologist at the BC Children's Hospital, and a Clinician Scientist at the BC Children's Hospital Research Institute. He is also the Director of the Pediatric Multi-Organ Transplant Program at BC Children's Hospital and Associate Professor in the UBC Department of Pediatrics.

Dr. Blydt-Hansen's research program will use proven techniques to identify signs of kidney injury and rejection in the urine of children who have had a kidney transplant. It will focus on the first year after transplant, since this is the highest risk for rejection. They will look for metabolites and chemokines that they have tested before to identify when injury or rejection is present. They already know some of the changes that occur with rejection. They now plan to validate that the same changes are present in other Canadian children with kidney transplants.

Graduate Student Supervision

Master's Student Supervision

Theses completed in 2010 or later are listed below. Please note that there is a 6-12 month delay to add the latest theses.

Investigating the impact of extended-release tacrolimus on adherence and graft outcomes in pediatric kidney transplant recipients (2021)

Improvements seen in short-term kidney transplant survival over the preceding three decades have not been reflected in long-term graft outcomes. This is particularly pertinent in the pediatric population, who experience high rates of graft failure, a large proportion of which are attributed to non-adherence. Extended-release tacrolimus (ER-Tac), taken once daily, is associated with improved adherence in adults but this has not been extensively studied in pediatric kidney transplant recipients. This study assessed 1) the clinical factors that influence conversion to ER-Tac 2) whether conversion to ER-Tac is associated with improved adherence and 3) whether conversion to ER-Tac is associated with improved allograft function and rejection outcomes. The first analysis showed that older age and female sex predicted conversion to ER-Tac. Adherence measures (medication adherence measure (MAM-MM) and tacrolimus trough variability (Tac CV%)), individual barriers to adherence, renal function, and rejection were not significant predictors of conversion. In the second analysis, we found that baseline adherence in this population was high and that ER-Tac was not subsequently associated with improved Tac CV% or self-reported adherence. Children were more likely to miss their morning medication and listed forgetfulness or schedule clashes as their most common reason to be non-adherent. Likewise, in the third analysis, ER-Tac was not superior to IR-Tac with regards to preventing rejection, decline in eGFR or graft loss. Older age and female sex have been associated in other studies with poorer allograft outcomes and perhaps act as a high-level risk assessment for conversion to ER-Tac based on perception of risk. We did not find that age or sex were strongly associated with adherence or outcomes in multivariable analyses in this study. The lack of association between ER-Tac and adherence may be explained by a high baseline adherence in this population and because patients were not selected for conversion based on adherence behaviour. The finding of stable late graft outcomes between IR-Tac and ER-Tac remains important, especially given patient preference for ER-Tac regarding convenience and quality of life reported in other studies.

View record


If this is your researcher profile you can log in to the Faculty & Staff portal to update your details and provide recruitment preferences.


Learn about our faculties, research and more than 300 programs in our 2022 Graduate Viewbook!